Home / Peptides / BPC-157: What the Research Shows and What It Doesn't
BPC-157: What the Research Shows and What It Doesn't
BPC-157 is not FDA-approved. What human and animal studies show, the Oct. 30, 2026 HHS enforcement policy, what it is not, and known risks.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Limited human data
- Status verified
BPC-157 is one of the most talked-about peptides online and one of the least studied in people. On Oct. 30, 2026, a new federal policy changed how pharmacies can handle it. It did not change what the research shows.
Key takeaways
- BPC-157 is not FDA-approved for any use. It is not a component of an approved drug, and FDA says it is not a component of an approved product in any country.
- No benefit has been shown in humans. FDA, assessing BPC-157 for ulcerative colitis, described a “lack of evidence” of effectiveness. The human reports are few and small, and much of the rest comes from animal studies.
- The Oct. 30, 2026 HHS policy is not an approval. HHS said it does not intend to take enforcement action against certain compounding of BPC-157 acetate, under conditions. The policy is interim and open to public comment.
- Long-term safety in humans is unknown.
- Athletes: BPC-157 is prohibited by WADA at all times.
What is BPC-157?
BPC-157 is reported to be a 15-amino-acid fragment of a protein originally isolated from human gastric juice. It has no FDA-approved product, no USP/NF monograph, and is not a component of any approved drug, according to FDA.
What did HHS do on Oct. 30, 2026?
The Department of Health and Human Services published an interim enforcement discretion policy covering six peptides, BPC-157 among them. In plain terms: HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians who compound BPC-157 acetate under section 503A, if all of its conditions are met. For BPC-157 the covered routes are subcutaneous, intramuscular, oral and topical (policy appendix).
The conditions include exact identification of the substance, batch-level testing, a registered and CGMP-compliant manufacturer, adverse-event reporting, a “compounded drug product” label, a single active ingredient, a patient-specific prescription and, for oral products, documentation of human oral bioavailability.
What the policy is not
- It is not FDA approval. The policy itself notes that FDA does not review compounded drugs.
- It does not add BPC-157 to any compounding list. It applies until a final rule includes or excludes the substances.
- It does not create rights. HHS can revise it, for example after a safety or quality signal.
- It does not cover blends. A mix of BPC-157 and TB-500 involves two active ingredients, which the policy does not cover (Frier Levitt, secondary source).
- It does not replace state law, according to a law-firm analysis (secondary source).
- Before the policy was issued, boards in Alabama and Mississippi told licensees they may not compound, administer or dispense non-FDA-approved or research-grade peptides. We found no update from them as of Oct. 31, and it isn’t clear how those notices apply to compounding under the HHS policy.
- It is open for public comment. The docket (HHS-OASH-2026-0496) lists a closing date of Nov. 13, 2026 (Eastern time). The document itself calls the policy both a policy and a draft; we describe it as interim.
How did FDA’s own reviewers see it?
Before the policy, FDA’s drug center proposed not adding BPC-157 to the compounding list, and FDA’s advisory committee voted 8–6–1 in favor of listing it (McDermott, secondary source). FDA evaluated BPC-157 only for ulcerative colitis. A legal analysis estimates a final rule could take 12–24 months (Frier Levitt, secondary source).
BPC-157 was in FDA’s “Category 2” (substances that may present significant safety risks) from September 2023 until April 22, 2026. HHS says that neither entering nor leaving that category changed its legal status.
What does the human research show?
Short answer: nothing that establishes benefit. The main sources are FDA’s presentations to its advisory committee and its briefing document.
| Study | Design | Participants | Limitation |
|---|---|---|---|
| Ruenzi 2005, ulcerative colitis, enema | Randomized, placebo-controlled trial; conference abstract only | 53 | FDA says details are missing and describes a “lack of evidence” |
| Lee & Padgett 2021, knee, intra-articular | Retrospective, no control group; some patients also received thymosin beta-4 | 17 (per FDA) | Cannot separate BPC-157’s effect from other factors |
| Lee 2024, interstitial cystitis, intravesical | Pilot, no control group | 12 (per FDA) | No comparison group |
| Lee & Burgess 2025, intravenous safety | Pilot study, no control group | 2 | Two people |
| Veljaca 2002/2003, healthy volunteers, enema | Randomized, placebo-controlled phase 1 tolerability and pharmacokinetic study; abstracts only | 32 randomized, 24 of them on BPC-157 (per FDA) | Tested tolerability and how the body handles the peptide, not whether it treats a condition |
FDA found no human studies of BPC-157 by oral, subcutaneous, nasal or transdermal routes, and its list of human studies does not include the intramuscular route. The HHS policy covers subcutaneous, intramuscular, oral and topical forms.
Is anything underway?
A randomized pilot after rotator cuff surgery (NCT07803250, 30 people, University of Arkansas) is registered but was not yet recruiting when we checked. It has no results.
What about the animal studies?
A 2026 scoping review of six peptides, including BPC-157, found that 67% of the publications it identified used preclinical animal models. It describes effects in tendon, muscle, bone and ligament models as “promising but variable” across those peptides, and concludes that their claimed benefits remain unsubstantiated by current human trials. Results from animals do not transfer to people reliably, and lab-dish findings are not clinical evidence.
What are the risks?
- Limited safety information. FDA cites “insufficient clinical safety information” and says the human studies were short and small. No serious adverse events appear to have been reported in those studies, but FDA says the authors gave limited safety data and that monitoring in most of them is unclear.
- Signals in animals. In 28-day toxicology studies in rats and dogs given intramuscular injections, FDA cited signals potentially related to blood clotting and the liver.
- Immune reactions. FDA flagged a potential for immune reactions, especially with injected or nasal use, potentially amplified by clumping and impurities.
- Adverse event reports. FDA’s reporting system holds three reports, with uncertain causality: an injection-site reaction; shortness of breath leading to an emergency visit; and skin and gum darkening that returned on re-exposure, in a person using BPC-157 with TB-500. The system is voluntary, and few reports do not mean the drug is safe.
- Identity and quality. FDA found salts and derivatives sold under the same name and concluded that the free base and acetate forms are not well characterized.
- Theoretical long-term concerns. A physician quoted by Healio said some of the peptides in the policy act on tissue growth and cellular aging, that long-term questions involve cancer risk, and that there is very little human data to answer them. That comment was about the group, not BPC-157 alone.
Where do the HHS policy and FDA’s assessment disagree?
HHS says “multiple human studies” support its policy, but the text we read does not cite them. FDA found no human studies of BPC-157 by several of the routes the policy covers. HHS also refers to batch certificates of analysis that it does not publish. Both views are on the record; we do not resolve them for you.
Is BPC-157 allowed in sport?
No. WADA prohibits it at all times, class S0 (non-approved substances) (2026 list).
Which claims about BPC-157 are false or unproven?
- “FDA approved it” or “it’s legal now.” Neither. It is under interim enforcement discretion, with conditions.
- “It heals tendons and joints.” No randomized human trial shows that.
- “It has no side effects.” Side effects have not been measured well.
- “Capsules work like injections.” FDA found no human oral studies, and HHS requires oral products to document human bioavailability.
- “It comes from human stomach juice, so it’s natural and safe.” That does not follow.
- “BPC-157 plus TB-500 in one blend is covered.” The policy covers single-ingredient products only.
What should you ask a doctor?
- Is there an approved treatment for my condition, and what does the evidence say about it?
- If BPC-157 is suggested, which condition is it for, and what human evidence supports it?
- Who prepares it, and does it meet the policy’s conditions (identity, testing, labeling)?
- What do we do if I have a reaction?
We do not give doses, cycles or preparation instructions for BPC-157, and we do not recommend sellers. For injuries, see our guide to peptides for injury recovery.
Frequently asked questions
Is BPC-157 FDA-approved?
No.
Is BPC-157 legal?
That is not a yes-or-no question. On Oct. 30, 2026, HHS said it does not intend to take enforcement action against certain compounding of BPC-157 acetate, under conditions. That is an interim enforcement position, not an approval and not a legalization.
Does BPC-157 work?
The human evidence does not establish that it does. FDA identified one small controlled effectiveness trial, reported only as a conference abstract, and describes a “lack of evidence”. A second controlled study, a phase 1 study in healthy volunteers, looked at tolerability, not effectiveness.
Is BPC-157 safe?
Its safety in humans has not been established. Absence of reports is not evidence of safety.
Is BPC-157 banned for athletes?
Yes, prohibited by WADA at all times.
Sources we checked
- Alabama Board of Medical Examiners: notice on prescribing non-FDA-approved research-grade peptidesOther. Accessed .
- Mississippi nursing, pharmacy and medical licensure boards: joint statement on peptides (Aug. 19, 2026)Other. Accessed .
- FDA presentations to the Pharmacy Compounding Advisory Committee (July 23, 2026)FDA. Accessed .
- FDA briefing document on BPC-157FDA. Accessed .
- FDA CDER proposal on seven peptides (July 2026)FDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS policy, Appendix BOther. Accessed .
- Regulations.gov docket HHS-OASH-2026-0496Other. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- Frier Levitt analysis of the HHS policy (secondary source)Other. Accessed .
- Healio: HHS further loosens restrictions for several peptidesOther. Accessed .
- WADA 2026 Prohibited ListOther. Accessed .
- Lee & Padgett 2021, knee injections (PubMed)PubMed. Accessed .
- Lee 2024, interstitial cystitis (PubMed)PubMed. Accessed .
- Lee & Burgess 2025, intravenous safety (PubMed)PubMed. Accessed .
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed .
- ClinicalTrials.gov NCT07803250 (rotator cuff pilot, not yet recruiting)ClinicalTrials.gov. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.